Ab­b­Vie stays bull­ish on fu­ture per­for­mance as Skyrizi con­tin­ues to im­press — but 'price con­trol­s' would be a game chang­er

Ab­b­Vie’s ex­ec­u­tive team stayed right on track in Q2, with its Skyrizi fran­chise — now new­ly ap­proved for Crohn’s — con­tin­u­ing to rack up im­pres­sive sales, mak­ing up for some un­ex­pect­ed weak­ness from a stronger dol­lar. The ero­sion of the Im­bru­vi­ca fran­chise, how­ev­er, dragged down the stock price $AB­BV 5% Fri­day.

That set the stage for a bull­ish pre­sen­ta­tion by CEO Rick Gon­za­lez, who care­ful­ly steered the con­ver­sa­tion around the loom­ing loss of US ex­clu­siv­i­ty with Hu­mi­ra to the for­mu­la­ry dis­cus­sions now un­der­way that would al­low the megabrand to con­tin­ue to gen­er­ate rev­enue in 2023 and 2024, as Ab­b­Vie’s new­er en­tries be­came bet­ter es­tab­lished and some hot pipeline picks get a chance to prove them­selves in piv­otal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER